FORFIVO XL (bupropion hydrochloride) by Lavipharm is unknown, as is the case with other antidepressants. First approved in 2011.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
FORFIVO XL is an extended-release oral tablet formulation of bupropion hydrochloride, an atypical antidepressant approved in 2011. It works through presumed noradrenergic and dopaminergic mechanisms by weakly inhibiting neuronal reuptake of norepinephrine and dopamine, without affecting serotonin or monoamine oxidase. The exact mechanism of action remains incompletely understood, as with most antidepressants.
With LOE approaching in 2.2 years and only $414K in Part D spending, this is a niche, declining product with minimal commercial infrastructure investment.
unknown, as is the case with other antidepressants. However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine, and does not inhibit monoamine oxidase or the…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions
Worked on FORFIVO XL at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
This product currently has zero linked job postings and minimal commercial momentum, making it a poor career choice for growth-oriented professionals. Positions on FORFIVO XL teams will likely focus on managed decline, cost containment, and generic transition planning through 2028.